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Effect of CYP2C9 polymorphisms on prescribed 
dose and time-to-stable dose of sulfonylureas in 
primary care patients with Type 2 diabetes mellitus
Sulfonylureas (SUs) are part of the mainstay of 
treatment of Type 2 diabetes mellitus (T2DM) 
with oral antidiabetic drugs. They act by closing 
the pancreatic b-cell potassium channels, stimu-
lating insulin secretion [1]. SUs are initiated at a 
low dose and titrated up to the optimal dose with 
intervals of 2–4 weeks until the glycemic target 
is achieved. Undertreatment will increase the risk 
of long-term microvascular and macro vascular 
complications, whereas overtreatment will lead 
to hypoglycemia, a well recognized adverse event 
that limits rapid dose escalation and is reported 
to be fatal in 1.4–10% of cases [2].
The enzyme CYP2C9 plays an important 
role in the pharmacokinetics of SUs. Two 
allelic variants, CYP2C9*2 and CYP2C9*3, 
result in decreased metabolic capacity. Both 
alleles are relatively common in Caucasians 
[101]. Most of the available data regarding the 
effect of CYP2C9 polymorphisms on SU treat-
ment originate from pharmacokinetic analyses 
performed in healthy individuals [3–9]. Only 
four studies have assessed the effect of CYP2C9 
polymorphisms in T2DM patients. Presence of 
the CYP2C9*3 allele was associated with hypo-
glycemia [10,11]. Furthermore, the CYP2C9*3 
allele is associated with the absence of tol-
butamide dose escalation and carriers of the 
CYP2C9*2 or CYP2C9*3 allele are less likely to 
fail on SU monotherapy [12,13]. However, none 
of these studies have assessed the effect of the 
CYP2C9 genotype on the time required for SU 
dose titration. Therefore, the aim of this study 
was to investigate the effect of CYP2C9*2 and 
CYP2C9*3 alleles on prescribed dose and time-
to-stable dose of SUs in T2DM patients in a 
primary care setting. 
Materials & methods
  Study setting
In The Netherlands patients are listed with 
one family physician (FP) who is consulted for 
all healthcare problems and indicates whether 
referral to secondary care is appropriate. The FP 
keeps an electronic patient record (EPR) that 
covers all medical information, including pre-
scription data concerning the patient. T2DM 
patients are treated according to the T2DM 
guideline of the Dutch College of General 
Practitioners [14]. 
  Study population
Patients were recruited from four univer-
sity aff iliated primary care centers located 
in the vicinity of Leiden, The Netherlands. 
Approximately 37,000 patients were enlisted. 
Retrospective clinical and prescription data 
were retrieved from the EPR. Patients were eli-
gible for the study if they had received at least 
one prescription of tolbutamide, glibenclamide, 
glimepiride or gliclazide after 1992, were at least 
18 years of age and were without insulin use at 
the time of first SU prescription and had at least 
270 days of follow-up registered in the EPR. To 
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ascertain that a SU prescription was the first, a 
period of at least 6 months without SU prescrip-
tions prior to that prescription recorded in the 
EPR was required.
  Sample collection
Eligible patients received a written invitation 
by mail from their FP. After consent, a saliva 
collection kit (DNA Genotek, ON, Canada) 
was mailed. The ethics committee of the 
Leiden University Medical Center approved 
the study and informed consent was obtained 
from all participants.
  Genotyping
Genotyping of CYP2C9*2 (rs1799853) and 
CYP2C9*3 (rs1057910) was performed by a 
TaqMan® allelic discrimination assay (Applied 
Biosystems, CA, USA), independently and with-
out knowledge of the patient data. Assays were 
used according to the manufacturer’s instruc-
tions and performed on 10 ng genomic DNA. 
Fluorescence detection and genotype calling were 
performed using an ABI Prism® 7750 Sequence 
Detection System (Applied Biosystems). 
  Definition of effect of CYP2C9*2 
& CYP2C9*3 alleles on SU dose & 
time-to-stable dose
The primary end point of our study was the 
effect of the CYP2C9*2 and CYP2C9*3 alleles 
on the stable SU dose. This was defined as the 
first period of 270 consecutive days or more 
without SU dose adjustment, or initiation 
or adjustment of therapy with another SUs, 
insulin or metformin. Dose was normalized to 
allow for the pooling of different SUs by divid-
ing the prescribed daily dose with the stan-
dard daily dose used by the Dutch Healthcare 
Insurance Board (10 mg glibenclamide; 
1000 mg tolbutamide; 160 mg gliclazide; 
2 mg glimepiride) [15]. The period of 270 days 
or more was chosen because prescriptions in 
The Netherlands are limited to a maximum 
of 90 days, and 270 days or more equals three 
consecutive prescriptions. 
The secondary end points of our study were 
the effect of CYP2C9*2 and CYP2C9*3 alleles 
on the time to the first stable SU dose, and the 
effect of the CYP2C9*2 and CYP2C9*3 alleles 
on the number of dose adjustments during the 
first year of SU treatment. Finally, the effect of 
the CYP2C9*2 and CYP2C9*3 alleles on the 
change in fasting glucose levels was analyzed 
in a subset of the cohort with measurements 
available 90 days before and during stable dose.
  Statistical ana lysis
A difference in stable dose of 0.33 was con-
sidered to be clinically relevant. According to 
the T2DM guidelines of the Dutch College of 
General Practitioners this equals a difference in 
titration time of approximately 4 weeks. In the 
power ana lysis, we calculated that 120 patients 
were to be included in order to test for statistical 
difference at a two-sided 5% significance level 
with at least 80% power. 
The data were analyzed using the SPSS sta-
tistical package (version 16.0, SPSS, IL, USA). 
Possible deviation from Hardy–Weinberg equi-
librium was tested by the c2 test. Differences in 
stable SU dose, number of dose adjustments, 
and fasting glucose levels were analyzed with 
Kruskal–Wallis nonparametric tests and multi-
variate linear regression ana lysis. All demo-
graphic and clinical variables were tested uni-
variately against stable SU dose. The variables 
with a p-value of less than 0.1 were selected for 
multivariate analysis. In addition, age, gender 
and genotype were included in the multivariate 
analysis regardless of their univariate p-value.
Associations between the CYP2C9*2 and 
CYP2C9*3 alleles and time-to-stable dose 
were evaluated using Kaplan–Meier survival 
ana lysis techniques. 
Results
Figure 1 depicts the study population. In total, 207 
T2DM patients were available for data ana lysis. 
Table 1 presents the patient characteristics. The 
mean age at the time of first SU prescription was 
61.5 years and 52.2% of the study population 
were men. Mean follow-up was 6.0 years, reflect-
ing that most patients (74.4%) were included after 
1st January 2000. The majority of patients started 
with tolbutamide (42.5%) or glimepiride (39.6%). 
Patients received an average of 26 SU prescrip-
tions with a median duration of 90 days per pre-
scription. In total, 30.4% of the patients used 
metformin when they started SU treatment. The 
population was in Hardy–Weinberg equilibrium 
(c2 = 5.50; p = 0.14), indicating a low likelihood 
of selection bias or errors in genotyping.
Table 2 summarizes the effect of the CYP2C9*2 
and CYP2C9*3 alleles on the SU dose. The mean 
starting dose was 0.62. As expected, no differences 
in mean starting dose were observed between the 
genotype groups. Of the 207 T2DM patients, 152 
(73.4%) achieved stable dose. There were no sta-
tistically significant differences in the percentage 
of patients that achieved stable dose between car-
riers of the CYP2C9*2 (70.7%) and/or CYP2C9*3 
(77.5%) allele compared with homozygous carriers 
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of the CYP2C9*1 (79.4%) allele (p = 0.48). For 
mean stable glimepiride dose, a trend towards 
a lower dose for carriers of a CYP2C9*3 allele 
in comparison to homozygous carriers of the 
CYP2C9*1 allele was observed (1.01 vs 0.61; 
p = 0.07).
To identify possible associations between 
demographic and clinical variables and stable 
SU dose, univariate regression ana lysis was per-
formed. The SU starting dose and the use of 
metformin were associated with the mean stable 
SU dose (Table 3). To adjust for the effects of 
metformin and initial SU dose, a multi variate 
regression ana lysis with CYP2C9 genotype, 
age and sex was performed. In summary, the 
results remained similar to the data as presented 
in Table 2.
Since SUs are titrated to the optimal 
dose, an ana lysis of the time-to-stable SU 
dose and CYP2C9 genotype was performed. 
Median time-to-stable dose was 56, 50 
and 48 days for homozygous carriers of the 
CYP2C9*1 allele, carriers of the CYP2C9*2 
allele or the CYP2C9*3 allele, respectively. 
The Kaplan–Meier curves for time-to-stable 
dose demonstrated no significant differences 
between carriers of the CYP2C9*1, CYP2C9*2 
or CYP2C9*3 alleles (p = 0.58) (Figure 2). For 
all CYP2C9 genotypes, approximately 35% 
of the patients achieved stability without any 
dose adjustment from the first prescription. 
The mean number of dose adjustments in the 
first year of SU therapy was 1.02 (range: 0–6) 
for all patients, and did not differ between the 
genotype groups with 0.95 dose adjustments 
for homozygous carriers of the CYP2C9*1 
allele, 1.22 dose adjustments for carriers of the 
CYP2C9*2 allele and 1.06 dose adjustments 
for carriers of the CYP2C9*3 allele (p = 0.24). 
Table 1. Characteristics of the Type 2 diabetes mellitus patient population in primary care.





Subjects 207 133 (64.3) 40 (19.3) 34 (16.4) NA
Men 108 (52.2) 73 (54.9) 18 (45.0) 17 (50.0) 0.53
Women 99 (47.8) 60 (45.1) 22 (55.0) 17 (50.0)
Age, mean (SD), years 61.5 (10.7) 61.2 (11.1) 61.8 (10.7) 62.3 (8.8) 0.85
Follow-up,  
mean (SD), years
6.0 (3.0) 5.8 (3.0) 6.3 (3.1) 6.1 (2.9) 0.68
Visits year 1 (SD) 9.6 (4.67) 9.9 (5.03) 9.5 (3.73) 8.8 (4.23) 0.20
Metformin 63 (30.4) 45 (33.8) 7 (17.5) 11 (32.4) 0.14
Primary sulfonylureas
Glibenclamide 12 (5.8) 8 (6.0) 3 (7.5) 1 (2.9) 0.03¶
Tolbutamide 88 (42.5) 45 (33.8) 24 (60.0) 19 (55.9)
Gliclazide 25 (12.1) 29 (15.8) 2 (5.0) 2 (5.9)
Glimepiride 82 (39.6) 59 (44.4) 11 (27.5) 12 (35.3)
†Unless stated otherwise.
‡4 patients were carriers of the CYP2C9*2/*2 genotype.
§1 patient was a carrier of the CYP2C9*2/*3 genotype.
¶c2 for primary sulfonylureas vs genotype group.
NA: Not applicable; SD: Standard deviation.
Eligible patients
n = 497 
Inclusion criteria
–  ≥ 1 SU prescriptions
– ≥ 6 months enlisted at FP before first SU prescription
– ≥270 days follow-up after first SU prescription
– ≥18 years of age
– No insulin
Invited patients
n = 472 (95.0%)
Included patients
n = 222 (47.0%)
Patients available for genotyping
n = 209 (94.1%)
Patients available for analysis
n = 207 (99.0%)
25 patients (5.0%) excluded by FP 
Reasons for exclusion were terminal 
disease status, impaired cognitive 
function, did not have Type 2
250 patients (53.0%) did not consent
13 patients (5.9%) did not provide a 
saliva sample
2 samples (0.9%) failed genotyping
diabetes mellitus
Figure 1. study population.
FP: Family physician; SU: Sulfonylurea.
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In addition, differences in fasting glucose lev-
els were assessed for the CYP2C9 genotypes. For 
75 patients (49.3%), fasting glucose level mea-
surements were available in the period 90 days 
prior to the first SU prescription and during 
stable SU dose. Fasting glucose levels decreased 
with 2.8, 2.6 and 2.4 mmol/l for homozygous 
carriers of the CYP2C9*1 allele, carriers of the 
CYP2C9*2 allele, and carriers of the CYP2C9*3 
allele, respectively (p = 0.89). 
discussion
In this retrospective study of 207 primary care 
patients with T2DM, no statistically signifi-
cant effect of the CYP2C9*2 and CYP2C9*3 
alleles on the prescribed stable dose or time-
to-stable dose of SUs was found. However, a 
trend towards a lower stable dose for carriers 
of the CYP2C9*3 allele was observed, in the 
subgroup of patients treated with glimepiride. 
Table 2. Prescribed dose of sulfonylurea at first and stable prescription stratified by CYP2C9 genotype group in 
Type 2 diabetes mellitus patients in primary care†.
dose, mean (sd) CYP2C9*1/*1 n CYP2C9*1/*2 or 
CYP2C9*2/*2




First 0.61 (0.25) 133 0.66 (0.31) 40 0.55 0.61 (0.26) 34 0.91
Stable 0.92 (0.59) 94 0.94 (0.45) 31 0.49 0.80 (0.37) 27 0.48
Glibenclamide
First 0.63 (0.23) 8 0.58 (0.38) 3 0.63 0.25 (NA) 1 0.06
Stable 0.75 (0.42) 6 1.00 (0.41) 4 0.30 1.50 (NA) 1 0.16
Tolbutamide
First 0.58 (0.20) 45 0.65 (0.23) 24 0.23 0.63 (0.28) 19 0.59
Stable 0.90 (0.47) 35 0.78 (0.31) 15 0.56 0.86 (0.41) 14 0.86
Gliclazide
First 0.64 (0.35) 21 0.88 (0.88) 2 0.95 0.75 (0.35) 2 0.48
Stable 0.78 (0.45) 13 0.88 (0.88) 2 0.86 0.83 (0.29) 3 0.78
Glimepiride
First 0.63 (0.26) 59 0.66 (0.36) 11 0.96 0.58 (0.19) 12 0.65
Stable 1.01 (0.74) 40 1.15 (0.53) 10 0.21 0.61 (0.22) 9 0.07
Patients were allowed to switch from SU in the period between the first prescribed SU and stable dose. As a consequence the number of patients may differ  
within SU. 
†To allow pooling of different SUs, dose was normalized by dividing the prescribed daily dose with the standard daily dose used by the Dutch Healthcare Insurance 
Board (10 mg glibenclamide, 1000 mg tolbutamide, 160 mg gliclazide and 2 mg glimepiride). 
NA: Not applicable; SD: Standard deviation; SU: Sulfonylurea.





95% CI p-value difference in 
change† 
95% CI p-value
Constant 0.912 0.307–1.516 0.003
Male vs  
female gender
-0.190 -0.355 to -0.025 0.024 -0.15 -0.32–0.02 0.083
The effect of age  
(per year increase)
-0.005 -0.013–0.004 0.280 -0.005 -0.014–0.003 0.218
Metformin use vs no 
metformin use at stable 
sulfonylurea dose
0.142 -0.038–0.321 0.120 0.177 -0.01–0.361 0.060
Carrier of CYP2C9*2 
allele vs wild-type
0.001 -0.209–0.211 0.992 0.041 -0.171–0.254 0.701
Carrier of CYP2C9*3 
allele vs wild-type
-0.088 -0.307–0.130 0.425 -0.129 -0.352–0.094 0.254
First sulfonylurea dose 0.583 0.266–0.899 0.000 0.569 0.253–0.885 0.000
†This considers the change in stable sulfonylurea dose (expressed as the prescribed daily dose divided by the standard daily dose used by the Dutch Healthcare 
Insurance Board).
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Since no difference in stable dose or time-to-
stable dose between the different genotypes 
was observed, we hypothesized that carriers of 
the CYP2C9*2 and CYP2C9*3 alleles might 
have a larger decrease in fasting glucose levels. 
There was however, no significant difference 
in decrease in fasting glucose levels during 
stable dose between carriers of the CYP2C9*2 
or CYP2C9*3 alleles and homozygous carriers 
of the CYP2C9*1 allele in the relatively small 
subgroup of patients with fasting glucose level 
measurements available. 
Our study has some limitations. In gen-
eral, observational studies may potentially be 
affected by bias. The FPs were unaware of the 
genotype, thereby excluding this information 
bias. In our study, no data was available for 
patients who had switched to another family 
practice or who died in the period after 1992. 
As a consequence, we cannot completely rule 
out the possibility of selection bias. However, 
our population was in Hardy–Weinberg equi-
librium, suggesting that no selection bias on 
genotype occurred. Moreover, a nonresponse 
ana lysis on age, gender, type of first prescribed 
SU, metformin use and FP revealed no dif-
ferences between participants and patients 
who did not consent to our study, indicat-
ing that no selection bias on any of these 
parameters occurred. 
The ana lysis of time-to-stable dose assumes 
that FPs adhere to the T2DM guideline of 
the Dutch College of General Practitioners. 
In general, adherence to guidelines by Dutch 
FPs is good [16]. If FPs do not adhere to the 
guideline, they can initiate treatment with 
a different dose or follow different titration 
intervals. In both situations this could intro-
duce an error to our analyses of time-to-stable 
dose. However, there is no reason to assume 
that this error is not divided randomly over the 
different genotype groups. Therefore it does 
not affect the comparison of time-to-stable 
dose between the genotype groups but can only 
affect the absolute results of the time-to-stable 
dose analyses.
The CYP2C9 genotype is known to have a 
significant effect on the pharmacokinetics of 
SUs in healthy volunteers [3–7,9]. Less infor-
mation is available regarding the effect of the 
CYP2C9 genotype in T2DM patients. Two 
retrospective studies assessed the effect of the 
CYP2C9*2 and CYP2C9*3 alleles on treat-
ment outcomes with SUs. Becker et al. found 



















































n               Median time to stable dose (days)
133 56
40                                        50
                        34                                        48
χ2,2 = 1.11, p = 0.58
Figure 2. kaplan–Meier survival plots of time to the first stable dose of sulfonylurea in 
Type 2 diabetes mellitus patients in primary care stratified by CYP2C9 genotype.
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that carriers of the CYP2C9*3 allele treated 
with tolbutamide received significantly lower 
doses on the arbitrarily chosen 10th prescrip-
tion compared with patients with the wild-
type genotype, No such effect was found for 
any of the other assessed SUs [12]. In addition, 
Zhou et al. observed a trend towards a 5% dose 
increase for patients with none or one copy ver-
sus no dose increase in carriers of two copies of 
the CYP2C9*2 or CYP2C9*3 alleles in patients 
who were mainly treated with gliclazide mono-
therapy [13]. We report similar findings towards 
a lower stable SU dose for patients with a 
CYP2C9*3 allele for a population of whom 
approximately 40% of the patients is treated 
with glimepiride. These findings indicate that 
the CYP2C9*3 allele inf luences the treat-
ment of T2DM patients with SUs. However, 
although inconclusive, our study suggests that 
the effect is probably small and we therefore 
feel that there is currently insufficient evidence 
to support the genotyping of CYP2C9 prior to 
prescribing SUs to an individual. 
The pathogenesis of T2DM is not yet fully 
understood. Current theories include defects 
in insulin-mediated glucose uptake in muscle, 
dysregulation of the adipocyte as a secretory 
organ, dysfunction of the pancreatic b-cell and 
impaired insulin action in the liver [17]. Several 
studies including linkage ana lysis, candidate 
gene approaches and genome-wide association 
studies have identified 20 common genetic 
variants associated with T2DM reflecting the 
disease’s multifaceted genetic background [18]. 
Probably as a consequence of this hetero geneity, 
interpatient variability of drug response remains 
largely unexplained. It is possible that the mul-
tifaceted genetic background of T2DM sur-
passes the effect of the CYP2C9 genotype on 
SU response. Therefore, there may be subpopu-
lations of T2DM patients in which the effect of 
the CYP2C9*2 and CYP2C9*3 alleles may be 
of clinical relevance. 
Conclusion
In conclusion, no association between the 
CYP2C9*2 or CYP2C9*3 alleles and time-to-
stable dose was found in T2DM patients in 
primary care, whereas carriers of a CYP2C9*3 
allele showed a trend towards a lower sta-
ble glimepiride dose. However, there are 
many other factors inf luencing SU treat-
ment outcome. Therefore, the effect of the 
CYP2C9*2 and CYP2C9*3 alleles currently 
has no clinical implications to dosing of SUs 
in T2DM patients.
executive summary
  The enzyme CYP2C9 plays an important role in the pharmacokinetics of sulfonylureas (SUs), but only four studies have assessed the 
effect of CYP2C9 polymorphisms in Type 2 diabetes mellitus (T2DM) patients.
  CYP2C9*2 and CYP2C9*3 alleles have been associated with hypoglycemia, absence of tolbutamide dose escalation and carriers have 
been proven to be less likely to fail on SU treatment.
  The aim of this study was to investigate the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and time-to-stable dose of 
SUs in T2DM in a primary care setting.
Materials & methods
  T2DM mellitus patients with a SU prescription were recruited from four university affiliated primary care centers. 
  The primary end point was the effect of the CYP2C9*2 and CYP2C9*3 alleles on the stable SU dose. 
  Secondary end points were the effect on the time to the first stable SU dose and the effect on the number of dose adjustments during 
the first year of SU treatment. 
  In an additional analysis, the effect of the CYP2C9*2 and CYP2C9*3 alleles on fasting glucose levels was assessed in patients for whom 
a fasting glucose level measurement was available in the period 90 days prior to the first SU prescription and during stable SU dose.
Results
  In this study of 207 incident SU users with T2DM, no statistically significant effect of the CYP2C9*2 and CYP2C9*3 alleles on the stable 
dose was found. 
  However, a trend towards a lower stable dose for carriers of the CYP2C9*3 allele, compared with homozygous carriers of the CYP2C9*1 
allele, was observed in the subgroup of patients treated with glimepiride (0.61 vs 1.01, p = 0.07).
  Of the patients, 152 (73.4%) achieved stable dose with a median time-to-stable dose of 56, 50 and 48 days for homozygous carriers of 
the CYP2C9*1 allele, carriers of the CYP2C9*2 and CYP2C9*3 alleles, respectively (p = 0.58).  
Discussion
  No significant effects of the CYP2C9*2 and CYP2C9*3 alleles were found on time-to-stable dose in T2DM patients in primary care, 
whereas carriers of the CYP2C9*3 allele show a trend towards a lower stable glimepiride dose. 
  Besides CYP2C9 genotype, there are many other factors influencing SU treatment outcome.
Conclusion
  Genotyping for the CYP2C9*2 and CYP2C9*3 alleles currently appears to have no clinical implications for dosing of SUs in primary care 
patients with T2DM.
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